2023 Volume 36 Pages 21-25
Background: The optimal treatment for C3 glomerulopathy remains undefined. Methods: 10 cases of C3 glomerulopathy diagnosed at our hospital between January 1, 2011 and September 30, 2021 were included in this study. We evaluated the proportion of C3 glomerulopathy, clinical course, treatment, and efficacy. Results: 10 cases of C3 glomerulopathy were included. 9 of the 10 patients were initially treated with steroid pulse and Mizoribine (“MZR”) and 1 with predonisolon alone. The median urine protein creatinine ratio (UP/C) on admission was 1.34 g/g・Cre. At 1 month after initial treatment, the median UP/C decreased to 0.42 g/g・Cre, and all patients improved; 6 patients were subsequently added or changed from MZR to cyclosporine (“CyA”), and the median UP/C reduced from 0.92 g/g・Cre to 0.13 g/g・Cre in 4 patients after more than six months post initiation of CyA. Conclusion: Multidrug therapy, including steroids and MZR as initial treatment, was successful. If initial treatment was inadequate or ineffective, CyA was considered as an effective option.
